Why the study?
Does simvastatin reduce inflammatory attacks in patients with hyper-IgD syndrome and mevalonate kinase deficiency?
Population
6 patients with hyper-IgD syndrome and proven mevalonate kinase deficiency
Comparison
Simvastatin 80 mg/d for 24 weeks vs Placebo for 24 weeks
Design
RCT, double-blind
Follow-up
24 weeks per treatment period
Authors
Loading...
Simvastatin may reduce attacks in hyper-IgD syndrome; extends evidence for statin anti-inflammatory effects in mevalonate kinase deficiency.
Does simvastatin reduce inflammatory attacks in patients with hyper-IgD syndrome and mevalonate kinase deficiency?
Simvastatin may improve inflammatory attacks in hyper-IgD syndrome, highlighting the anti-inflammatory properties of HMG-CoA reductase inhibition.
Anna Simon (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: